0001104659-24-004523.txt : 20240117 0001104659-24-004523.hdr.sgml : 20240117 20240117170100 ACCESSION NUMBER: 0001104659-24-004523 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240115 FILED AS OF DATE: 20240117 DATE AS OF CHANGE: 20240117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Norry Elliot CENTRAL INDEX KEY: 0001798117 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37368 FILM NUMBER: 24539175 MAIL ADDRESS: STREET 1: C/O ADAPTIMMUNE THERAPEUTICS PLC STREET 2: 60 JUBILEE AVE, MILTON PARK CITY: ABINGDON, OXFORDSHIRE STATE: X0 ZIP: OX14 4RX ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptimmune Therapeutics PLC CENTRAL INDEX KEY: 0001621227 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 60 JUBILEE AVENUE STREET 2: MILTON PARK CITY: ABINGDON, OXFORDSHIRE STATE: X0 ZIP: OX14 4RX BUSINESS PHONE: 44 1235 430000 MAIL ADDRESS: STREET 1: 60 JUBILEE AVENUE STREET 2: MILTON PARK CITY: ABINGDON, OXFORDSHIRE STATE: X0 ZIP: OX14 4RX FORMER COMPANY: FORMER CONFORMED NAME: Adaptimmune Ltd DATE OF NAME CHANGE: 20141001 4 1 tm243270-6_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-01-15 0 0001621227 Adaptimmune Therapeutics PLC ADAP 0001798117 Norry Elliot C/O ADAPTIMMUNE THERAPEUTICS PLC 60 JUBILEE AVENUE, MILTON PARK ABINGDON X0 OX14 4RX UNITED KINGDOM 0 1 0 0 Chief Medical Officer 0 Option to purchase Ordinary Shares 0.14 2024-01-15 4 A 0 2544432 0 A 2034-01-15 Ordinary Shares 2544432 2544432 D Option to purchase Ordinary Shares 0.0013 2024-01-15 4 A 0 565416 0 A Ordinary Shares 565416 565416 D The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount. Exercisable as to 636,108 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in monthly installments of 53,004 Ordinary Shares on the fifteenth of each month from February 15, 2025 through December 15, 2027 and 53,184 Ordinary Shares on January 15, 2028. The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount. Exercisable as to 141,354 Ordinary Shares on January 15, 2025 and will be exercisable as to the remainder in annual installments of 141,354 Ordinary Shares on the fifteenth of each January from January 15, 2026 through January 15, 2028. The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable. /s/ Elliot Norry 2024-01-17